Where does Turning Point Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Turning Point Therapeutics, Inc. ranks #17,300 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Turning Point Therapeutics, Inc. hold?

Turning Point Therapeutics, Inc. holds 17 US utility patents granted between 2020 and 2025, spanning 7 technology areas.

What is Turning Point Therapeutics, Inc.'s Innovation Score?

Turning Point Therapeutics, Inc. has an Innovation Score of 39.1 out of 100 (top 39% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Turning Point Therapeutics, Inc. focus on?

Turning Point Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 15 patents, ranking #1,291 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Turning Point Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Turning Point Therapeutics, Inc..

What does claim depth mean for Turning Point Therapeutics, Inc.'s patents?

Turning Point Therapeutics, Inc.'s patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Turning Point Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Turning Point Therapeutics, Inc.

USPTO PatentsView assignee record - 17 granted patents across 7 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Turning ranks #17,300 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 7 technology areas.

#17,300
of 49,997 US assignees by volume: Top 39%
by Innovation Score (39.1/100): 18.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R17300 · US Corporation #17,300 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 17 grants
MID-PACK #17,300/49,997
PHOTO-FINISH Tallinn University…
CPC-NARROW A61P · 7 areas
INNOV-THIN 39.1/100
CLAIMS-RICH 18.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Tallinn University of Technology (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Turning’s 39.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (26%) Velocity 8.9 pts (23%) Breadth 9.4 pts (24%) Claim depth 10.8 pts (28%)

Qualcomm Incorporated · highest

85
GKN Driveline North… · near

39
Numecent Holdings · near

39
Tokai Kogyo · near

39
Teco Image Systems · near

39
Turning Point… · this assignee

39
3D Lighting… · lowest

7

What this shows Turning's Innovation Score is 39.1/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Turning?

Each dot is one of Turning’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Turning’s own 18.1 claims/patent is ABOVE the 13.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Turning vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Turning's grants concentrate

Turning Point Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 88.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2024. By volume, Turning sits between Toyo Automation Co., Ltd. and Techfields Pharma Co., Ltd..

Turning's three-year grant acceleration

Turning Point Therapeutics, Inc. shows 8 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Toyo Automation

17
Triplay

17
Trizell

17
Turbo Systems Swi…

17
Turtle Bear Holdi…

17
Tallinn Universit…

17
Tech Pharmacy Ser…

17
Techfields Pharma

17
Turning Point The… ◀

17

What this shows Turning holds 17 patents at rank #17,271, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Turning

By rank, the assignees closest to #17,271 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Turning's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Turning, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Turning ranks #1,291 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Teco Image Systems Co., Ltd. 39 GKN Driveline North America, Inc. 39 Tokai Kogyo Co., Ltd. 39 Numecent Holdings, Inc. 39

Turning's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 39% higher than 61% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Turning Point Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	3	17.6%
2021	3	17.6%
2022	4	23.5%
2023	3	17.6%
2024	1	5.9%
2025partial year	3	17.6%

Which technologies does Turning Point Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 15

C07D - Heterocyclic Compounds 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07K - Peptides 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07C - Acyclic OR Carbocyclic Compounds 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Turning Point Therapeutics, Inc.'s patent record in context - here's where to go next.

Turning Point Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,300 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Turning Point Therapeutics, Inc. against Toyo Automation Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.